Microbe-associated immunomodulatory metabolites: Influence on T cell fate and function

Molecular Immunology

Volumn 68, Issue 2, 2015, Pages 575-584

  Castro, C N ^a   Freitag, J ^a   Berod, L ^a   Lochner, M ^a   Sparwasser, T ^a  

^a INSTITUTE OF INFECTION IMMUNOLOGY   (Germany)

Author keywords

Fatty acid synthesis; Glycolysis; Immunometabolism; Meta MAMPs; Rapamycin; Soraphen A; T cell fate

Indexed keywords

ACETYL COENZYME A CARBOXYLASE; ADENOSINE TRIPHOSPHATE; ANTISENSE OLIGONUCLEOTIDE; COLECALCIFEROL; CONJUGATED LINOLEIC ACID; CORTICOSTEROID; CYCLOSPORIN; CYCLOSPORIN A; IMMUNOMODULATING AGENT; LIPOXIN; LIPOXYGENASE; LONG CHAIN FATTY ACID; NICOTINAMIDE ADENINE DINUCLEOTIDE; PATTERN RECOGNITION RECEPTOR; PROSTAGLANDIN E2; RAPAMYCIN; RETINOIC ACID; SORAPHEN A; SUCCINIC ACID; UNCLASSIFIED DRUG; VITAMIN B GROUP; VITAMIN B9; PATHOGEN ASSOCIATED MOLECULAR PATTERN;

ARTICLE; CELL FATE; CELL FUNCTION; FATTY ACID METABOLISM; HUMAN; IMMUNE RESPONSE; IMMUNOMODULATION; METABOLISM; METABOLITE; MICROORGANISM; MYXOCOCCALES; NONHUMAN; PRIORITY JOURNAL; REGULATORY T LYMPHOCYTE; STREPTOMYCES; T LYMPHOCYTE; T LYMPHOCYTE ACTIVATION; ANIMAL; IMMUNOLOGY; LYMPHOCYTE ACTIVATION;

ANIMALS; HUMANS; LYMPHOCYTE ACTIVATION; PATHOGEN-ASSOCIATED MOLECULAR PATTERN MOLECULES; T-LYMPHOCYTES;

EID: 84949099597     PISSN: 01615890     EISSN: 18729142     Source Type: Journal    
DOI: 10.1016/j.molimm.2015.07.025     Document Type: Article

References (118)

1. Abu-Elheiga L., Matzuk M.M., Abo-Hashema K.A., Wakil S.J. Continuous fatty acid oxidation and reduced fat storage in mice lacking acetyl-CoA carboxylase 2. Science 2001, 291:2613-2616. 10.1126/science.1056843.
2. Abu-Elheiga L., Oh W., Kordari P., Wakil S.J. Acetyl-CoA carboxylase 2 mutant mice are protected against obesity and diabetes induced by high-fat/high-carbohydrate diets. Proceed. Natl. Acad. Sci. U. S. A. 2003, 100:10207-10212. 10.1073/pnas.1733877100.
3. Abu-Elheiga L., Wu H., Gu Z., Bressler R., Wakil S.J. Acetyl-CoA carboxylase 2-/- mutant mice are protected against fatty liver under high-fat, high-carbohydrate dietary and de novo lipogenic conditions. J. Biol. Chem. 2012, 287:12578-12588. 10.1074/jbc.M111.309559.
4. Amato R.J., Jac J., Giessinger S., Saxena S., Willis J.P. A phase 2 study with a daily regimen of the oral mTOR inhibitor RAD001 (everolimus) in patients with metastatic clear cell renal cell cancer. Cancer 2009, 115:2438-2446. 10.1002/cncr.24280.
5. Arpaia N., et al. Metabolites produced by commensal bacteria promote peripheral regulatory T-cell generation. Nature 2013, 504:451-455. 10.1038/nature12726.
6. Atarashi K., et al. ATP drives lamina propria T(H) 17 cell differentiation. Nature 2008, 455:808-812. 10.1038/nature07240.
7. Atarashi K., et al. Induction of colonic regulatory T cells by indigenous Clostridium species. Science 2011, 331:337-341. 10.1126/science.1198469.
8. Azzi J.R., Sayegh M.H., Mallat S.G. Calcineurin inhibitors: 40 years later, can't live without. J. Immunol. 2013, 191:5785-5791. 10.4049/jimmunol.1390055.
9. Barbi J., Pardoll D., Pan F. Metabolic control of the Treg/Th17 axis. Immunol. Rev. 2013, 252:52-77. 10.1111/imr.12029.
10. Baselga J., et al. Everolimus in postmenopausal hormone-receptor-positive advanced breast cancer. N. Eng. J. Med. 2012, 366:520-529. 10.1056/NEJMoa1109653.
11. Beckers A., et al. Chemical inhibition of acetyl-CoA carboxylase induces growth arrest and cytotoxicity selectively in cancer cells. Cancer Res. 2007, 67:8180-8187. CAN-07-0389. 10.1158/0008-5472.
12. Berod L., et al. De novo fatty acid synthesis controls the fate between regulatory T and T helper 17 cells. Nat. Med. 2014, 20:1327-1333. 10.1038/nm.3704.
13. Blazar B.R., Taylor P.A., Sehgal S.N., Vallera D.A. Rapamycin, a potent inhibitor of T-cell function, prevents graft rejection in murine recipients of allogeneic T-cell-depleted donor marrow. Blood 1994, 83:600-609.
14. Brown C.C., Noelle R.J. Seeing through the dark: new insights into the immune regulatory functions of vitamin A. Eur. J. Immunol. 2015, 45:1287-1295. 10.1002/eji.201344398.
15. Brown E.J., et al. A mammalian protein targeted by G1-arresting rapamycin-receptor complex. Nature 1994, 369:756-758. 10.1038/369756a0.
16. Calne R.Y., et al. Rapamycin for immunosuppression in organ allografting. Lancet 1989, 2:227.
17. Chajes V., Cambot M., Moreau K., Lenoir G.M., Joulin V. Acetyl-CoA carboxylase alpha is essential to breast cancer cell survival. Cancer Res. 2006, 66:5287-5294. 10.1158/0008-5472.CAN-05-1489.
18. Chang C.H., et al. Posttranscriptional control of T cell effector function by aerobic glycolysis. Cell 2013, 153:1239-1251. 10.1016/j.cell.2013.05.016.
19. Chow J.D., et al. Genetic inhibition of hepatic acetyl-CoA carboxylase activity increases liver fat and alters global protein acetylation. Mol. Metab. 2014, 3:419-431. 10.1016/j.molmet.2014.02.004.
20. Corbett J.W., Harwood J.H. Inhibitors of mammalian acetyl-CoA carboxylase. Recent Patents Cardiovasc. Drug Discov. 2007, 2:162-180.
21. Delgoffe G.M., et al. The mTOR kinase differentially regulates effector and regulatory T cell lineage commitment. Immunity 2009, 30:832-844. 10.1016/j.immuni.2009.04.014.
22. Delgoffe G., et al. The kinase mTOR regulates the differentiation of helper T cells through the selective activation of signaling by mTORC1 and mTORC2. Nat. Immunol. 2011, 12:295-303. 10.1038/ni.2005.
23. Diken M., et al. mTOR inhibition improves antitumor effects of vaccination with antigen-encoding RNA. Cancer Immunol. Res. 2013, 1:386-392. CIR-13-0046. 10.1158/2326-6066.
24. Dorrestein P.C., Mazmanian S.K., Knight R. Finding the missing links among metabolites, microbes, and the host. Immunity 2014, 40:824-832. 10.1016/j.immuni.2014.05.015.
25. Dufort F.J., et al. Glucose-dependent de novo lipogenesis in B lymphocytes: a requirement for atp-citrate lyase in lipopolysaccharide-induced differentiation. J. Biol. Chem. 2014, 289:7011-7024. 10.1074/jbc.M114.551051.
26. Duvel K., et al. Activation of a metabolic gene regulatory network downstream of mTOR complex 1. Mol. Cell 2010, 39:171-183. 10.1016/j.molcel.2010.06.022.
27. Eisenreich W., Heesemann J., Rudel T., Goebel W. Metabolic host responses to infection by intracellular bacterial pathogens. Front. Cell. Infection Microbiol. 2013, 3:24. 10.3389/fcimb.2013.00024.
28. Everts B., et al. TLR-driven early glycolytic reprogramming via the kinases TBK1-IKKvarepsilon supports the anabolic demands of dendritic cell activation. Nat. Immunol. 2014, 15:323-332. 10.1038/ni.2833.
29. Favre D., et al. Tryptophan catabolism by indoleamine 2,3-dioxygenase 1 alters the balance of TH17 to regulatory T cells in HIV disease. Sci. Transl. Med. 2010, 6. 32ra36. 10.1126/scitranslmed.3000632.
30. Feldman M.E., Apsel B., Uotila A., Loewith R., Knight Z.A., Ruggero D., Shokat K.M. Active-site inhibitors of mTOR target rapamycin-resistant outputs of mTORC1 and mTORC2. PLoS biology 2009, 7:e38.
31. Fiedler W., et al. A phase I/II study of sunitinib and intensive chemotherapy in patients over 60 years of age with acute myeloid leukaemia and activating FLT3 mutations. Br. J. Haematol. 2015, 10.1111/bjh.13353.
32. Finlay D., Cantrell D. Phosphoinositide 3-kinase and the mammalian target of rapamycin pathways control T cell migration. Ann. N.Y. Acad. Sci. 2010, 1183:149-157. 10.1111/j.1749-6632.2009.05134.x.
33. Finlay D.K., et al. PDK1 regulation of mTOR and hypoxia-inducible factor 1 integrate metabolism and migration of CD8+ T cells. J. Exp. Med. 2012, 209:2441-2453. 10.1084/jem.20112607.
34. Furusawa Y., et al. Commensal microbe-derived butyrate induces the differentiation of colonic regulatory T cells. Nature 2013, 504:446-450. 10.1038/nature12721.
35. Gaboriau-Routhiau V., et al. The key role of segmented filamentous bacteria in the coordinated maturation of gut helper T cell responses. Immunity 2009, 31:677-689. 10.1016/j.immuni.2009.08.020.
36. Garcia R.O., Krug D., Muller R. Chapter 3. Discovering natural products from myxobacteria with emphasis on rare producer strains in combination with improved analytical methods. Methods Enzymol. 2009, 458:59-91. 10.1016/S0076-6879(09)4803-4.
37. Gaudet R.G., et al. INNATE IMMUNITY. Cytosolic detection of the bacterial metabolite HBP activates TIFA-dependent innate immunity. Science 2015, 348:1251-1255. 10.1126/science.aaa4921.
38. Gerth K., Bedorf N., Irschik H., Hofle G., Reichenbach H. The soraphens: a family of novel antifungal compounds from Sorangium cellulosum (Myxobacteria). I. Soraphen A1 alpha: fermentation, isolation, biological properties. J. Antibiot. 1994, 47:23-31.
39. Gerth K., Pradella S., Perlova O., Beyer S., Muller R. Myxobacteria proficient producers of novel natural products with various biological activities-past and future biotechnological aspects with the focus on the genus Sorangium. J. Biotechnol. 2003, 106:233-253.
40. Geuking M.B., et al. Intestinal bacterial colonization induces mutualistic regulatory T cell responses. Immunity 2011, 34:794-806. 10.1016/j.immuni.2011.03.021.
41. Gregory C.R., et al. Treatment with rapamycin blocks arterial intimal thickening following mechanical and alloimmune injury. Transplant. Proc. 1993, 25:120-121.
42. Harwood H.J. Acetyl-CoA carboxylase inhibition for the treatment of metabolic syndrome. Curr. Opin. Invest. Drugs 2004, 5:283-289.
43. Hintz M., et al. Identification of (E)-4-hydroxy-3-methyl-but-2-enyl pyrophosphate as a major activator for human gammadelta T cells in Escherichia coli. FEBS Lett. 2001, 509:317-322.
44. Ivanov I.I., et al. Induction of intestinal Th17 cells by segmented filamentous bacteria. Cell 2009, 139:485-498. 10.1016/j.cell.2009.09.033.
45. Jacinto E., et al. Mammalian TOR complex 2 controls the actin cytoskeleton and is rapamycin insensitive. Nat. Cell Biol. 2004, 6:1122-1128. 10.1038/ncb1183.
46. Jensen-Urstad A.P., Semenkovich C.F. Fatty acid synthase and liver triglyceride metabolism: housekeeper or messenger. Biochim. Biophys. Acta 2012, 1821:747-753. 10.1016/j.bbalip.2011.09.017.
47. Kinoshita M., et al. Dietary folic acid promotes survival of Foxp3+ regulatory T cells in the colon. J. Immunol. 2012, 189:2869-2878. 10.4049/jimmunol.1200420.
48. Klages K., et al. Selective depletion of Foxp3+ regulatory T cells improves effective therapeutic vaccination against established melanoma. Cancer Res. 2010, 70:7788-7799. 10.1158/0008-5472.CAN-10-1736.
49. Lahl K., et al. Selective depletion of Foxp3+ regulatory T cells induces a scurfy-like disease. J. Exp. Med. 2007, 204:57-63. 10.1084/jem.20061852.
50. Lee K., et al. Mammalian target of rapamycin protein complex 2 regulates differentiation of Th1 and Th2 cell subsets via distinct signaling pathways. Immunity 2010, 32:743-753. 10.1016/j.immuni.2010.06.002.
51. Lee J., et al. Regulator of fatty acid metabolism, acetyl coenzyme a carboxylase 1, controls T cell immunity. J. Immunol. 2014, 192:3190-3199. 10.4049/jimmunol.1302985.
52. Li Q., et al. A central role for mTOR kinase in homeostatic proliferation induced CD8+ T cell memory and tumor immunity. Immunity 2011, 34:541-553. 10.1016/j.immuni.2011.04.006.
53. Lochner M., et al. Restricted microbiota and absence of cognate TCR antigen leads to an unbalanced generation of Th17 cells. J. Immunol. 2011, 186:1531-1537. 10.4049/jimmunol.1001723.
54. Lochner M., Berod L., Sparwasser T. Fatty acid metabolism in the regulation of T cell function. Trends Immunol. 2015, 36:81-91. 10.1016/j.it.2014.12.005.
55. Mao J., et al. Liver-specific deletion of acetyl-CoA carboxylase 1 reduces hepatic triglyceride accumulation without affecting glucose homeostasis. Proc. Natl. Acad. Sci. U. S. A. 2006, 103:8552-8557. 10.1073/pnas.0603115103.
56. Martel R.R., Klicius J., Galet S. Inhibition of the immune response by rapamycin, a new antifungal antibiotic. Can. J. Phys. Pharmacol. 1977, 55:48-51.
57. Masui K., et al. mTOR complex 2 controls glycolytic metabolism in glioblastoma through FoxO acetylation and upregulation of c-Myc. Cell Metab. 2013, 18:726-739. 10.1016/j.cmet.2013.09.013.
58. McCully M.L., et al. Skin metabolites define a new paradigm in the localization of skin tropic memory T cells. J. Immunol. 2015, 195:96-104. 10.4049/jimmunol.1402961.
59. McGettrick F., O'Neill L. How metabolism generates signals during innate immunity and inflammation. J. Biol. Chem. 2013, 288:22893-22898. 10.1074/jbc.R113.486464.
60. Menendez J.A., Lupu R. Fatty acid synthase and the lipogenic phenotype in cancer pathogenesis. Nat. Rev. Cancer 2007, 7:763-777. 10.1038/nrc2222.
61. Michalek R.D., et al. Cutting edge: distinct glycolytic and lipid oxidative metabolic programs are essential for effector and regulatory CD4+T cell subsets. J. Immunol. 2011, 186:3299-3303. 10.4049/jimmunol.1003613.
62. Mockler M.B., Conroy M.J., Lysaght J.T. Targeting cell immunometabolism for cancer immunotherapy; understanding the impact of the tumor microenvironment. Front. Oncol. 2014, 4(107). 10.3389/fonc.2014.00107.
63. Morice W.G., Wiederrecht G., Brunn G.J., Siekierka J.J., Abraham R.T. Rapamycin inhibition of interleukin-2-dependent p33cdk2 and p34cdc2 kinase activation in T lymphocytes. J. Biol. Chem. 2015, 268(22):227-737.
64. Morris R. E. New small molecule immunosuppressants for transplantation: review of essential concepts. J. Heart Lung Transplant. 1993, 12:S275-286.
65. Morrisett J.D., Abdel-Fattah G., Kahan B.D. Sirolimus changes lipid concentrations and lipoprotein metabolism in kidney transplant recipients. Transplant. Proc. 2003, 35:143S-150S.
66. Motzer R.J., et al. Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial. Lancet 2008, 372:449-456. 10.1016/S0140-6736(08)61039-9.
67. Naing A., et al. Safety, tolerability, pharmacokinetics and pharmacodynamics of AZD8055 in advanced solid tumours and lymphoma. Br. J. Cancer 2012, 107:1093-1099. 10.1038/bjc.2012.368.
68. Napoli K.L., Taylor P.J. From beach to bedside: history of the development of sirolimus. Ther. Drug Monitor. 2001, 23:559-586.
69. Netzker T., et al. Microbial communication leading to the activation of silent fungal secondary metabolite gene clusters. Front. Microbiol. 2015, 6:299. 10.3389/fmicb.2015.00299.
70. O'Reilly K.E., Rojo F., She Q.B., Solit D., Mills G.B., Smith D., Lane H., Hofmann F., Hicklin D.J., Ludwig D.L., Baselga J., Rosen N. mTOR inhibition induces upstream receptor tyrosine kinase signaling and activates Akt. Cancer Res. 2006, 66:1500-1508.
71. O'Sullivan D., Pearce E.T. Tragetin cell metabolism for therapy. Trends Immunol. 2015, 36:71-80. 10.1016/j.it.2014.12.004.
72. Oh W., et al. Glucose and fat metabolism in adipose tissue of acetyl-CoA carboxylase 2 knockout mice. Proc. Natl. Acad. Sci. U. S. A. 2005, 102:1384-1389. 10.1073/pnas.0409451102.
73. Olson D.P., Pulinilkunnil T., Cline G.W., Shulman G.I., Lowell B.B. Gene knockout of Acc2 has little effect on body weight, fat mass, or food intake. Proc. Natl. Acad. Sci. U. S. A. 2010, 107:7598-7603. 10.1073/pnas.0913492107.
74. Pearce E.L., Poffenberger M.C., Chang C.H., Jones R.G. Fueling immunity: insights into metabolism and lymphocyte function. Science 2013, 342:1242454. 10.1126/science.1242454.
75. Pizer E., et al. Malonyl-coenzyme-A is a potential mediator of cytotoxicity induced by fatty-acid synthase inhibition in human breast cancer cells and xenografts. Cancer Res. 2000, 60:213-218.
76. Pollizzi K.N., Powell J.D. Regulation of T cells by mTOR: the known knowns and the known unknowns. Trends Immunol. 2015, 36:13-20. 10.1016/j.it.2014.11.005.
77. Pollizzi K.N., et al. mTORC1 and mTORC2 selectively regulate CD8+ T cell differentiation. J. Clin. Investig. 2015, 125:2090-2108. 10.1172/JCI77746.
78. Pridzun L., Sasse S., Reichenbach H. Antifungal Agents: Discovery and mode of Action 1995, 99-109. BIOS Scientific Publishers Ltd. G.K. Dixon, L.G. Copping, D.W. Hollomon (Eds.).
79. Ramsay G., Cantrell D. Environmental and metabolic sensors that control T cell biology. Front. Immunol. 2015, 6:99. 10.3389/fimmu.2015.00099.
80. Ravenschlag K., Sahm K., Pernthaler J., Amann R. High bacterial diversity in permanently cold marine sediments. Appl. Environ. Microbiol. 1999, 865:3982-3989.
81. Reichenbach H. The ecology of the myxobacteria. Environ. Microbiol. 1999, 1:15-21.
82. Renz H., et al. Gene-environment interactions in chronic inflammatory disease. Nat. Immunol. 2011, 12:273-277. 10.1038/ni0411-273.
83. Ricoult S.J., Manning B.D. The multifaceted role of mTORC1 in the control of lipid metabolism. EMBO Rep. 2013, 14:242-251. 10.1038/embor.2013.5.
84. Rosborough B.R., et al. Adenosine triphosphate-competitive mTOR inhibitors: a new class of immunosuppressive agents that inhibit allograft rejection. Am. J. Transplant. 2014, 4:2173-2180. 10.1111/ajt.12799.
85. Sarbassov D.D., et al. Prolonged rapamycin treatment inhibits mTORC2 assembly and Akt/PKB. Mol. Cell 2006, 22:159-168. 10.1016/j.molcel.2006.03.029.
86. Savage D.B., et al. Reversal of diet-induced hepatic steatosis and hepatic insulin resistance by antisense oligonucleotide inhibitors of acetyl-CoA carboxylases 1 and 2. J. Clin. Invest. 2006, 116:817-824. 10.1172/JCI27300.
87. Schreiber K.H., et al. Rapamycin-mediated mTORC2 inhibition is determined by the relative expression of FK506-binding proteins. Aging Cell 2015, 14:265-273. 10.1111/acel.12313.
88. Schreiber S.L. Chemistry and biology of the immunophilins and their immunosuppressive ligands. Science 1991, 251:283-287.
89. Schreurs M., et al. Soraphen, an inhibitor of the acetyl-CoA carboxylase system, improves peripheral insulin sensitivity in mice fed a high-fat diet. Diabetes Obes. Metab. 2009, 11:987-991. 10.1111/j.1463-1326.2009.01078.x.
90. Sehgal S.N., et al. Ravidomycin (AY-25,545), a new antitumor antibiotic. J. Antibiot. 1983, 36:355-361.
91. Shapiro H., Thaiss C.A., Levy M., Elinav E. The cross talk between microbiota and the immune system: metabolites take center stage. Curr. Opin. Immunol. 2014, 30:54-62. 10.1016/j.coi.2014.07.003.
92. Shen Y., Volrath S.L., Weatherly S.C., Elich T.D., Tong L. A mechanism for the potent inhibition of eukaryotic acetyl-coenzyme A carboxylase by soraphen A, a macrocyclic polyketide natural product. Mol. Cell 2004, 16:881-891. 10.1016/j.molcel.2004.11.034.
93. Shi Y., Burn P. Lipid metabolic enzymes: emerging drug targets for the treatment of obesity. Nat. Rev. Drug Discov. 2004, 3:695-710. 10.1038/nrd1469.
94. Sigmundsdottir H., et al. DCs metabolize sunlight-induced vitamin D3 to 'program' T cell attraction to the epidermal chemokine CCL27. Nat. Immunol. 2007, 8:285-293. 10.1038/ni1433.
95. Sinclair L.V., et al. Phosphatidylinositol-3-OH kinase and nutrient-sensing mTOR pathways control T lymphocyte trafficking. Nat. Immunol. 2008, 9:513-521. 10.1038/ni.1603.
96. Smith P.M., et al. The microbial metabolites, short-chain fatty acids, regulate colonic Treg cell homeostasis. Science 2013, 341:569-573. 10.1126/science.1241165.
97. Soefje S.A., Karnad A., Brenner A.J. Common toxicities of mammalian target of rapamycin inhibitors. Targeted Oncol. 2011, 6:125-129. 10.1007/s11523-011-0174-9.
98. Sreeramkumar V., et al. Efficient T cell priming and activation requires signalling through prostaglandin E2 (EP) receptors. Immunol. Cell Biol. 2015, 10.1038/icb.2015.62.
99. Stallone G., et al. ID2-VEGF-related pathways in the pathogenesis of Kaposi's sarcoma: a link disrupted by rapamycin. Am. J. Transplant. 2009, 9:558-566. 10.1111/j.1600-6143.2008.02537.x.
100. Stone R.M., et al. PhaseIII open-label randomized study of cytarabine in combination with amonafide -Malate or daunorubicin as induction therapy for patients With secondary acute myeloid leukemia. J. Clin. Oncol. 2015, 33:1252-1257. 10.1200/JCO.2014.57.0952.
101. Sun S.Y. mTOR kinase inhibitors as potential cancer therapeutic drugs. Cancer Lett. 2013, 340:1-8. 10.1016/j.canlet.2013.06.017.
102. Teng M.W., et al. Conditional regulatory T-cell depletion releases adaptive immunity preventing carcinogenesis and suppressing established tumor growth. Cancer Res. 2010, 70:7800-7809. 10.1158/0008-5472.CAN-10-1681.
103. Thoreen C.C., et al. An ATP-competitive mammalian target of rapamycin inhibitor reveals rapamycin-resistant functions of mTORC1. J. Biol. Chem. 2009, 284:8023-8032. 10.1074/jbc.M900301200.
104. Thupari J.N., Pinn M.L., Kuhajda F.P. Fatty acid synthase inhibition in human breast cancer cells leads to malonyl-CoA-induced inhibition of fatty acid oxidation and cytotoxicity. Biochem. Biophys. Res. Commun. 2001, 285:217-223. 10.1006/bbrc.2001.5146.
105. Todo S., et al. Immunosuppression of canine, monkey, and baboon allografts by FK 506: with special reference to synergism with other drugs and to tolerance induction. Surgery 1988, 104:239-249.
106. Vachier I., et al. Endogenous anti-inflammatory mediators from arachidonate in human neutrophils. Biochem. Biophys. Res. Commun. 2002, 290:219-224. 10.1006/bbrc.2001.6155.
107. Vahlensieck H.F., Pridzun L., Reichenbach H., Hinnen A. Identification of the yeast ACC1 gene product (acetyl-CoA carboxylase) as the target of the polyketide fungicide soraphen A. Curr. Genet. 1994, 25:95-100.
108. Vezina C., Kudelski A., Sehgal S.N. Rapamycin (AY-22,989), a new antifungal antibiotic. I. Taxonomy of the producing streptomycete and isolation of the active principle. J. Antibiot. 1975, 28:721-726.
109. Waickman A.T., Powell J.D. mTOR, metabolism, and the regulation of T-cell differentiation and function. Immunol. Rev. 2012, 249:43-58. 10.1111/j.1600-065X.2012.01152.x.
110. Wakil S.J., Abu-Elheiga L.A. Fatty acid metabolism: target for metabolic syndrome. J. Lipid Res. 2009, 50(Suppl):S138-S143. 10.1194/jlr.R800079-JLR200.
111. Wang R., Green D.R. Metabolic checkpoints in activated T cells. Nat. Immunol. 2012, 13:907-915. 10.1038/ni.2386.
112. Wang R., et al. The transcription factor Myc controls metabolic reprogramming upon T lymphocyte activation. Immunity 2011, 35:871-882. 10.1016/j.immuni.2011.09.021.
113. Weatherly S.C., Volrath S.L., Elich T.D. Expression and characterization of recombinant fungal acetyl-CoA carboxylase and isolation of a soraphen-binding domain. Biochem. J. 2004, 380:105-110. 10.1042/BJ20031960.
114. Weissman K.J., Muller R. A brief tour of myxobacterial secondary metabolism. Bioorg. Med. Chem. 2009, 17:2121-2136. 10.1016/j.bmc.2008.11.025.
115. Weissman K.J., Muller R. Myxobacterial secondary metabolites: bioactivities and modes-of-action. Nat. Prod. Rep. 2010, 27:1276-1295. 10.1039/c001260m.
116. Yang K., et al. T cell exit from quiescence and differentiation into Th2 cells depend on Raptor-mTORC1-mediated metabolic reprogramming. Immunity 2013, 39:1043-1056. 10.1016/j.immuni.2013.09.015.
117. Yao J.C., et al. Everolimus for advanced pancreatic neuroendocrine tumors. N. Eng. J. Med. 2011, 364:514-523. 10.1056/NEJMoa1009290.
118. Yatsunenko T., et al. Human gut microbiome viewed across age and geography. Nature 2012, 486:222-227. 10.1038/nature11053.